Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

171 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

NCT02473419

ADHD

COMPLETED

Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)

NCT02253745

ADHD

COMPLETED PHASE1/PHASE2

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

NCT02712996

Traumatic Brain Injury Attention Deficit Disorder

COMPLETED PHASE4

PK/PD Pediatric ADHD Classroom Study

NCT02536105

Attention Deficit Hyperactivity Disorder

COMPLETED NA

Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD

NCT00619840

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder (ADHD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence 1: Treatment/Treatment

Treatment/Treatment- consists of Vayarin® for 8 weeks followed by 8 weeks of additional treatment with Vayarin®

Group Type ACTIVE_COMPARATOR

Vayarin®

Intervention Type OTHER

Medical Food

Sequence 2: Placebo/Treatment

Placebo/Treatment- consists of Placebo for 8 weeks followed by 8 weeks of treatment with Vayarin®

Group Type ACTIVE_COMPARATOR

Vayarin®

Intervention Type OTHER

Medical Food

Placebo

Intervention Type OTHER

Cellulose

Sequence 3: Placebo/Placebo

Placebo/Placebo- consists of Placebo for 8 weeks followed by 8 weeks of additional treatment with Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Cellulose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vayarin®

Medical Food

Intervention Type OTHER

Placebo

Cellulose

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female age 18-60 inclusive.
2. Primary diagnosis of ADHD
3. At least 50% of the sample will have an abnormal score on the Emotional Control subscale of the BRIEF-A of ≥65.
4. AISRS total score ≥ 24
5. CGI-S ≥4 (moderately ill or worse).
6. Subjects in ongoing psychotherapy will be allowed, but no significant changes in the frequency, type or intensity of the therapy are to be made during the course of their study participation per the discretion of the principal investigator. The subject must be in psychotherapy at least 4 weeks prior to the screening visit.
7. Understands and is able, willing, and likely to fully comply with the study procedures and restrictions.
8. Has given written informed consent to participate in the study.

Exclusion Criteria

1. BMI less than18.5 or greater than 35.
2. Any underlying/ history or current diagnosis of systemic and/or metabolic disease (e.g. diabetes, Crohn's disease) and/or neurological condition state that may render the subject illegible to participate in the study as assessed by medical history, physical exam, clinical and lab evaluation.
3. History of uncontrolled hypertension or a resting systolic blood pressure \> 140mmHg or diastolic blood pressure \> 90mmHg (Subjects with well controlled hypertension on a stable dose (2 months) of anti-hypertensives will be allowed to participate).
4. Hamilton Anxiety Scale (HAM-A) ≥ 17).
5. Hamilton Depression scale (HAM-D ≥ 13).
6. Major depression or anxiety disorder which is a focus of treatment or requires taking medication.
7. A lifetime history of psychosis or bipolar disorder based on a clinician-administered interview using the Mini International Neuropsychiatric Interview (M.I.N.I 7.0). Subjects with mild to moderate forms of social phobia and dysthymia, not requiring treatment, will be allowed.
8. Has any concurrent chronic or unstable medical condition that could confound with the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
9. Subjects taking any medication with CNS effects (excluding subjects who discontinue the medications at least 2 weeks prior to the study for stimulants and 4 weeks for SSRI, non-stimulants, and alpha 2-agonist).
10. Subjects with a history of two or more prior failed adequate trials of ADHD treatment due to adverse events.
11. Use of dietary supplements with potential CNS effect, including omega-3 supplements, 30 days before study initiation and throughout the study.
12. Clinical history of cognitive impairment in judgment of investigator.
13. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed at screening visit prior to randomization. Women of childbearing potential must agree to use adequate birth control for the entire duration of the study.
14. Subjects with a current (within the last 3 months) DSM-V diagnosis of alcohol or drug abuse or dependence (excluding nicotine).
15. Known history of allergic reactions or sensitivity to marine products (fish and seafood), or soy.
16. Has taken an investigational drug or taken part in a clinical trial within 30 days prior to screening.
17. Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No